Introduction
Venezuelan equine encephalitis virus (VEEV) is a member of the genus Alphavirus in the family Togaviridae. VEEV causes periodic outbreaks of disease in Latin and South America and is an emerging pathogen [1] . VEEV is highly infectious in aerosol form in mice and non human primates [2, 3] and was characterized as a bioweapon [4] . VEEV has been designated a Category B priority pathogen by the National Institute of Allergy and Infectious Disease. VEEV is transmitted by mosquito in nature [5] [6] [7] and causes disease of varying severity in horses and humans [8, 9] .
There is no licensed vaccine available for prophylaxis against VEEV. A live attenuated TC-83 vaccine for VEEV is currently used under investigational new drug (IND) status and is administered to laboratory personnel at risk. However, TC-83 has residual virulence in suckling mice [10] and infection of pregnant mice with TC-83 results in stillbirth and decreased litter size of newborns [11] . TC-83 vaccine is also detrimental for the human fetus [12] . Further limitations of TC-83 vaccine in humans include short-lived immunity and approximately 20% non-responders [13, 14] . Formalin inactivated TC-83, known as C-84, is used as a booster following immunization with live, attenuated TC-83 vaccine. This vaccine is also used under IND status, has short-lived immunity and requires frequent boosts [14, 15] . An attenuated strain, V3526, which has a deletion mutation at the furin cleavage site between the E2 and E3 glycoproteins of the Trinidad donkey strain of VEEV [16] has been extensively evaluated as a VEEV vaccine candidate [17] [18] [19] [20] . V3526 has excellent immunogenic activity, but also causes febrile illness and low level neurotropism in non human primates [17, 18, [21] [22] [23] . In phase I clinical trial, V3526 induced a robust immune response; however, a high frequency of fever and a flu-like syndrome were reported which led to the cessation of the development of V3526 as a live attenuated vaccine [24, 25] .The residual virulence associated with the vaccine candidates has again focused the attention on the inactivated vaccine preparation. We have previously demonstrated that 1,5 iodonaphthyl azide (INA) completely inactivated the virulent strain of VEEV, V3000 in vitro [26] . INA is a hydrophobic photoactive aryl azide that sequesters in the hydrophobic domain of the biological membranes. Irradiation with ultra-violet light results in covalent binding of INA to lipids and proteins embedded in the membrane bilayer [27, 28] . This results in the inactivation of the membrane proteins without affecting the ectodomain of these proteins that is protruding outside the membrane bilayer [29, 30] . This mechanism of action of INA was exploited to inactivate other viruses such as HIV, SIV, Ebola and influenza virus [31] [32] [33] .
In this study, we have evaluated the safety and protective efficacy of INA inactivated-V3000 in mice. We also demonstrate in vitro that INA can efficiently inactivate the live attenuated vaccine strain V3526 of VEEV. These results are important as these establish a proof of concept that INA-inactivated VEEV is safe and immunogenic and can be further explored for developing an inactivated VEEV vaccine.
Materials and methods

Virus and animals
Virus: Molecularly cloned virulent strain of VEEV, V3000 [8] and an attenuated strain, V3526 [34] were used in the present study.
Animals: Swiss CD-1 mice, 5-6 weeks old and 1 day old CD-1 pups and dams were purchased from Charles River Laboratories, Wilmington, MA. Mice were housed in microisolator cages and were provided food and water ad libitum with a 12 h light/dark cycle. All experiments with V3000 virus strain were carried out in a bio-safety level 3 (BSL-3) facility at Uniformed Services University of The Health Sciences (USUHS), Bethesda, MD. All experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (Committee on Care And Use of Laboratory Animals of The Institute of Laboratory Animal Resources, National Research Council, NIH Publication No. 86-23, revised 1996).
Inactivation of VEEV with 1,5 iodonaphthylazide (INA)
INA was kindly provided by Drs. Robert Blumenthal and Yossef Raviv, National Cancer Research Institute, NIH Frederick, MD under a material transfer agreement. V3526 and V3000 were inactivated with INA as described before [26] . Briefly, purified viral stocks with known titers were suspended in 1× Dulbecco's Phosphate Buffered Saline (DPBS) (GIBCO, Invitrogen Corporation, Carlsbad, CA) at a protein concentration of 0.5 mg/ml. The preparations were then passed through 30 gauge needle syringe to disperse any viral aggregates in the suspension. Under reduced light conditions, 2-2.5 l aliquots of 20 mM INA were added to the virus suspension (final concentration 100 M) along the wall of an ultra clear 1.5 ml microcentrifuge tube (GeneMate, Catalog No. C-3269-1, ISC Bioexpress, Kaysville, UT) followed by immediate vortexing after each addition. Samples were incubated for 20 min in the dark at room temperature and then centrifuged at 1000 rpm for 1 min to remove any precipitated INA. The supernatant was transferred to a new tube and 20 l of 1 M glutathione was added at a final concentration of 20 M to quench any unbound INA present in the solution. The virus suspension was vortexed and irradiated using 100 W mercury UV lamp as described previously [26] . Briefly, the virus suspension was irradiated twice for 90 s and once for 120 s followed by vortexing each time. Thereafter full light conditions were used and samples were stored at −80 • C. Virus titers were back calculated and dilutions were made accordingly for testing the infectivity of INA-inactivated V3526 and INA-inactivated V3000. Therefore, all the doses of INA-inactivated V3526 and INA-inactivated V3000 are plaque forming unit (pfu) equivalent of corresponding virulent VEEV strain.
Determination of cytopathic effect (CPE assay)
Vero cells were plated in 24-well tissue culture plates and infected with V3526 or INA-inactivated V3526 at a multiplicity of infection (MOI) of 1.0 and incubated at 37 • C and 5% CO 2 incubator. Virus was removed after 1 h incubation and fresh media was added to the cells after washing once with 1× DPBS. Cells were observed for cytopathic effect such as rounding and sloughing off from the surface. At 72 h post-infection (p.i.) cell supernatants were collected from the wells and cells were stained with 0.1% crystal violet (CV) in 2% neutral buffered formalin (NBF) solution, for 10 min at room temperature (RT).
Virus titration by plaque assay
Virus titers in the brain of suckling mice were determined by standard plaque assay. Twenty percent (weight/volume) brain samples were prepared by homogenizing brain tissue in 1× PBS supplemented with 0.1% bovine serum. Nearly confluent monolayers of Vero cells in 60 mm culture dishes were incubated with serial dilutions of the samples for 1 h at 37 • C and 5% CO 2 incubator and then were rinsed once with 1× DPBS. Agarose overlay (1% agarose, 1× MEM, 6% newborn calf serum and 0.5% penicillin-streptomycin) was added to the cells and plates were incubated at 37 • C and 5% CO 2 incubator. Plaques were visualized and counted at 96 h p.i by staining the cells with 0.1% CV in 2% NBF solution for 10 min at RT.
Reverse transcription-PCR (RT-PCR)
Total RNA was isolated from the brains of intracranial (i.c.) inoculated V3526 (day 4 p.i.) and INA-inactivated V3526 (day 13 p.i.) mice using the TriZol reagent (Invitrogen Inc., Carlsbad, CA) according to manufacturer's protocol. Similarly total RNA was also isolated from Vero cells infected with V3526 and INA-inactivated V3526 (MOI = 10) at 48 h p.i.
cDNA was made from the total RNA using the SuperScript III First-Strand Synthesis kit (Invitrogen Inc., Carlsbad, CA) according to manufacturer's protocol. Briefly, 1 g of total RNA was mixed with 2.0 l of enzyme mix, 10 l of 2× buffer and nuclease free water was added to a final reaction volume of 20 l. The reaction mixture was incubated at RT for 10 min followed by incubation at 50 • C for 30 min and 85 • C for 5 min. Samples were kept on ice for 2 min and 1 l of RNaseH was added followed by an incubation at 37 • C for 20 min.
V3526 specific PCR for the nonstructural protein 4 (nsP4) gene (virus RNA dependent RNA polymerase) was performed to evaluate the virus infection in vitro. GAPDH served as a house keeping gene. Primer sequences used for nsP4 gene were: Forward-5 GCTAACAGAAGCAGATACCAG3 ; Reverse-5 GCAGCCGAATCCAATACGGGC3 . Primer sequences used for GAPDH gene were: Forward-5 CCATCACCATCTTCCAGGAGCGAG3 ; Reverse-5 CACAGTCTTCTGGGTGGCAGTGAT3 . PCR supermix (Invitrogen Inc., Carlsbad, CA) was used to perform the PCR. Reaction mixture consisted of 45 l of PCR supermix, 1 l (30 ng) of each primer and 2 l of cDNA. The following PCR cycle was used: initial denaturation at 95 • C for 3 min, followed by 25 cycles of denaturation at 95 • C for 30 s, annealing at 62 • C for 45 s, and extension at 72 • C for 30 s. A final extension was done at 72 • C/5 min.
Evaluation of virus genome for infectivity
The RNA genome was isolated from 500 l of INA-inactivated V3000 and similarly diluted 500 l of virulent V3000 using PureLink viral RNA/DNA mini kit (Invitrogen, Carlsbad, CA) as per manufacturer's protocol. RNA was eluted into a final volume of 20 l. RNA from two samples was pooled together and quantitated using a Beckman 640 spectrophotometer (Beckman instruments Inc., Columbia, MD, USA). RNA, was transfected into cells using the siPORT Amine transfection reagent (Applied Biosystems/Ambion, Austin, TX) as per manufacturer's protocol. Briefly, the RNA (100 g) was mixed with the transfection reagent and incubated at room temperature for 20 min. Following the incubation, BHK cells suspended in fresh 1× MEM medium (without antibiotics) were added to the RNA transfection mixture and plated in 8-well chamber slides. After 12 h, the transfection reagent mix was removed and replaced with fresh 1× MEM media (with antibiotics). Cells were incubated for 48 h and then fixed with chilled 1:1::acetone:methanol solution for 10 min. Slides were then stored at −20 • C until stained for VEEV antigen as described below. 2.7. Immunofluorescence for VEEV antigen V3000 ( Fig. 1) and V3526 (Fig. 4) antigen specific immunofluorescence was done as described previously [26] . Briefly, slides were rinsed thrice with 1× PBS for 5 min each and nonspecific binding was blocked using 1% BSA for 1 h at room temperature. Excess BSA was removed and slides were incubated with 1:1000 diluted polyclonal rabbit anti-VEEV antibody (kindly provided by Dr. Franziska B. Grieder, USUHS, Bethesda, MD) for 1 h at 37 • C. Slides were then rinsed thrice with 1× PBS for 5 min each and incubated with FITCconjugated goat anti-rabbit IgG (1:1000) for 30 min at 37 • C. This antibody recognizes both V3526 and V3000 strains of VEEV. Slides were washed thrice with 1× PBS for 5 min each, mounted with vectashield mounting medium containing DAPI (Vector laboratories, Inc., Burlingame, CA), and were observed under fluorescence microscope.
Residual virulence evaluation in suckling mice
For the entire in vivo study, stock virus suspension was diluted to desired working suspension in 1× DPBS.
Suckling mice study with V3000 and V3526: Five day old mice were infected intraperitoneally (i.p.) with 10,000 pfu of virulent V3000 or INA-inactivated V3000 (n = 9 or n = 10, respectively) in a final volume of 20 l. Nine day old mice were infected intracranially (i.c.) with 10,000 pfu of INA-inactivated V3000 (n = 10) or virulent V3000 (n = 9) in a final volume of 20 l. Three days old mice were infected i.c. with 10,000 pfu of V3526 (n = 8) or INAinactivated V3526 (n = 10) in a final volume of 20 l. Control mice (n = 2) were similarly injected with 1× phosphate buffered saline (PBS). Animals were observed for a period of 2 weeks for the development of any clinical signs of disease and infection. Brain tissues were collected from all mice at the end of two weeks observation period and were stored at −80 • C.
Immunization and protection study
Three separate immunization studies were undertaken. Five to six weeks old male CD-1 mice were injected intraperitoneally with the INA-inactivated V3000 on day zero. At 7th day post last vaccination, mice were challenged with virulent V3000 virus. Mice were anesthetized using inhalation anesthesia, isofluorane using a "drop jar method" as described before [35] and 1000 pfu of virulent V3000 were inoculated in the rear footpad of each mouse.
First study: n = 6. Booster doses were given at day 7 post first immunization (pfi) and day 14 pfi. Immunization consisted of 10,000 INA-inactivated pfu of V3000. Six age-matched nonvaccinated mice were included as control. On the day 21 pfi, blood was collected by tail vein nick and serum was isolated. Mice were then challenged with virulent V3000 strain of VEEV.
Second study: n = 10 per group. Booster doses were given at days 7, 14 and 21 pfi. First two booster doses consisted of 10,000 pfu of INA-inactivated V3000 and the third booster dose consisted of 50,000 pfu of INA-inactivated V3000. On the day 28 pfi blood was collected by tail vein nick and serum was isolated. On day 29 pfi mice were challenged with virulent V3000. Three individual groups were examined: (1) INA-inactivated V3000 alone. Mice were immunized with the INA-inactivated V3000 formulation alone for all four immunizations. (2) INA-inactivated V3000 with Alhydrogel as adjuvant. Alhydrogel ® (Brenntag Biosector, Fredeikssund, Denmark) was first diluted to a working suspension containing 2 mg/ml of aluminum in 1× DPBS. INA-inactivated V3000 was mixed with diluted Alhydrogel in equal volumes. This mixture was then continuously vortexed for 2 h at room temperature. Animals were given four immunizations of this INA-inactivated V3000-Alhydrogel formulation. (3) INA-inactivated VEEV with Complete Freund's adjuvant (CFA). INA-inactivated V3000 was mixed with the equal volume of CFA just prior to immunization. Only the first immunization was given with the INA-inactivated V3000-CFA formulation and the subsequent three immunizations contained only INA-inactivated V3000. Ten age-matched non-vaccinated mice were included as controls.
Third-study: Nineteen mice were immunized with 50,000 pfu at day zero followed by two booster immunizations with 50,000 pfu each at day 7 and day 14 pfi. Five age-matched non-vaccinated mice were included as control. On day 21 pfi, mice were challenged with virulent V3000 strain of VEEV.
In all the three studies mice were monitored for the clinical symptoms of disease and mortality for 14 days after challenge with virulent virus.
Enzyme-linked immunosorbent assay for detecting anti-VEEV antibody in serum
Blood was incubated on ice for 30 min and then centrifuged at high speed for 30 min. The aqueous layer of serum was then collected and immediately stored at −80 • C. For enzyme-linked immunosorbent assay (ELISA), 96 well Immulon 4HBX ultra-high binding polystyrene microtiter plates (Thermo Electron Corp., Milford, MA) were coated with 5 g of virulent V3000 strain of VEEV per well in 50 l volume at 4 • C overnight. The virus suspension was then removed and plates were blocked with 1% Bovine Serum Albumin (BSA) (50 l/well) at 4 • C overnight. Blocking agent was then removed and 50 l serially diluted serum (1:50, 1:250, 1:625 and 1:1250) was added to wells in triplicates. Plates were then incubated for 4 h at 37 • C followed by two washes, first with 0.05% Tween 20 in 1× PBS and then with distilled water. An aliquot (50 l) of alkaline phosphatase conjugated goat anti-mouse IgG (secondary antibody) (1:1000) was added to each well and incubated at 37 • C for 1 h. Plates were then washed twice first with 0.05% Tween 20 in 1× PBS and then with distilled water. Phosphatase substrate (Sigma-Aldrich, St. Louis, MO) was then added (50 l/well of 5 mg/ml) and color was allowed to develop for 10 min at 37 • C. Plates were read at 405 nm wavelength using ELISA reader (Bio-Rad Laboratories, Inc., Hercules, CA 94547).
Results and discussion
In our previous study [26] we demonstrated that V3000 virus, rescued from a cDNA of VEEV [8] , can be completely inactivated with INA in vitro. In this study we tested the safety and protective efficacy of INA-inactivated V3000 in mice. To test the residual virulence that may be associated with the INA-inactivated VEEV, suckling mice were inoculated with INA-inactivated V3000 and were observed for disease morbidity. Suckling mice are immunologically immature and fail to or induce inadequate antibody response to infection [36] . The immature neurons are also more susceptible to virus induced apoptosis [37] . Therefore, these mice should be sensitive to any residual virulence that may be associated with inactivated preparations of virus. None of the suckling mice infected with INA-inactivated V3000 (i.p. or i.c.) showed any clinical sign of disease and survived the two week observational period ( Table 1 ). Mice that received V3000 succumbed to the virus infection within 48 h p.i. The positive sense RNA genome of alphaviruses is infectious and when transfected into sensitive cell lines results in the generation of live virus particles [38, 39] . BHK cells were transfected with RNA isolated from INA-inactivated V3000. Immunofluorescence staining for VEEV antigen showed that RNA isolated from INA-inactivated V3000 was non-infectious. Positive VEEV staining was observed in the cells that were transfected with RNA isolated from virulent V3000. The staining was similar to that of V3000 virus infection. The cells that were transfected with the RNA from INA-inactivated V3000 did not show any staining for VEEV antigen and were similar to that of negative controls (Fig. 1) .
These results indicate that INA may have another mechanism of virus inactivation independent of protein binding. This is a novel finding as INA was only known to inactivate virus by binding to the viral proteins [31, 40] . Since VEEV RNA is infectious, its inactivation by INA may further reduce the residual virulence that may be associated with infectious RNA of otherwise inactivated VEEV. Incompletely inactivated VEEV vaccine was believed to be responsible for some of the outbreaks of VEEV [1] . Thus inactivation of VEEV RNA by INA may provide another level of protection against incomplete inactivation seen with other inactivation methods. Further studies are in progress to evaluate interaction of INA with viral RNA.
To test the efficacy of INA-inactivated VEEV to induce protective antibody response a proof of concept study with INAinactivated V3000 was undertaken. Mice were immunized with INA-inactivated V3000 as described in Section 2. In the first study, 3 doses of 10,000 pfu equivalents of INA-inactivated V3000 induced a 60% protective response in mice (data not shown). To evaluate if additional immunization and use of adjuvant increase the protection efficacy we gave an additional immunization dose and used Alhydrogel and CFA adjuvant in the second study. Alhydrogel is an approved adjuvant for human use and has been shown to increase the protection in gamma irradiated V3526 immunized mice [41] . CFA is also a potent adjuvant and was used to compare the response to Alhydrogel and to determine if use of adjuvant increases the protective efficacy. INA-inactivated V3000 alone still Table 2 Immunization with INA-inactivated VEEV protected mice from virulent VEEV challenge.
Group(s)
Vaccine study (10,000 pfu) protection (%) (total died/total mice)
Vaccine study (50,000 pfu) protection (%) (total died/total mice) conferred 60% protection. In, adjuvanted INA-inactivated V3000 groups the protective efficacy increased to 80% and 90% with the use of CFA and Alhydrogel, respectively (Table 2) . Since increasing the number of immunizations did not affect the protective efficacy of INA-inactivated V3000 alone, we next tested the effect of increasing the immunization dose of INA-inactivated V3000 to 50,000 pfu equivalents. Protection against virulent V3000 increased to 80% from 60% as was seen with 10,000 pfu equivalent dosages. As expected, all the non-immunized mice succumbed to challenge with virulent VEEV (Table 2) . None of the mice inoculated with the INA-inactivated V3000 in the above three studies showed any clinical symptoms of disease such as hunched back, anxiety, loss of appetite and hind limb paralysis. Though further experiments are needed to establish complete protective dose of INA-inactivated V3000, these experiments demonstrate the protective efficacy of INA-inactivated V3000. The serum antibody response was variable in the group vaccinated with INA-inactivated V3000 alone, some mice had an antibody titer of >log 10 2.1 and some mice had titers <log 10 2.0. Use of CFA resulted in a more uniform antibody response compared to the INA-inactivated V3000 alone group that was approximately log 10 2.1. Use of Alhydrogel resulted in a uniformly higher antibody response (p = 0.00036) compared to the INA-inactivated V3000 alone group (Fig. 2 ). Adjuvants such as CpG and Alhydrogel have been shown to enhance the antibody titers and protection in mice immunized with gamma irradiated V3526 [41] . These results are similar to those demonstrated by others with influenza and Ebola viruses where INA-inactivated viruses induced protective antibody response to respective viruses [32, 33] . We also demonstrate in vitro that INA can efficiently inactivate the live attenuated vaccine strain V3526 of VEEV. Live attenuated V3526 has shown excellent protective efficacy in animal models [17, 18] and robust immune response in phase I clinical trial [25] . However, its development as a live attenuated vaccine was halted due to a flu-like syndrome and fever in the recipients [24, 25] . Therefore, it will be desirable to inactivate V3526 in a way that conserves its immunogenicity to generate a safer vaccine candidate without any residual virulence. Since INA inactivates virulent VEEV strain, V3000 [26] and has been shown to conserve (Fig. 3A) . Treatment of cells with free INA showed no toxicity up to 200 M dosages ruling out any cell death due to free INA in the solution (Supplementary Fig. 1 ). No virus replication was detected either in the supernatant of or in the cells infected with INA-inactivated V3526 (Fig. 3B and  C) . Immunofluorescence staining for V3526 antigen in the cells infected with the INA-inactivated V3526 also did not show any VEEV specific staining (Fig. 4) . These results corroborated our previous findings with V3000 strain of VEEV [26] and also with other reports of inactivation of influenza, Ebola, HIV and SIV viruses by INA [31] [32] [33] . Further RNA isolated from the INA-inactivated V3526 did not show any infectivity (Supplementary Fig. 2 ). We also tested the INA-inactivated V3526 for any residual virulence in suckling mice. Suckling mice inoculated i.c. with V3526 developed the disease and either succumbed to the infection within 48-96 h p.i. or were humanely euthanized at 96 h p.i. due to disease morbidity such as stunted growth, slow breathing rate and little to no movement (Table 1 ). None of the mice which received INA-inactivated V3526 showed any clinical symptoms of disease such as, hunched posture, stunted growth, lethargic or paralysis and grew similar to that of the control mice. Further studies are in progress to evaluate the protective efficacy of INA-inactivated V3526.
These results have significant implications as INA-inactivated VEEV overcomes the residual virulence reported with the vaccine strains for VEEV, i.e. TC-83, V3526 without potentially degenerating the surface antigenic epitopes as seen with formalin inactivation. INA-inactivation also appears to render the positive sense RNA genome non-infectious thereby inactivating by two independent mechanisms of inactivation and thus has an added advantage over the existing methods of inactivation. VEEV is endemic in the Central and South America and has long been considered a potential biothreat agent. Current IND TC-83 vaccine has limited use due to 20% non responder rate and poor protection from other subtypes of VEEV. Therefore, there remains an urgent need for an effective vaccine for immunization against VEEV. These results show that INA-inactivated VEEV is safe and can protect against virulent VEEV challenge in mice. Therefore, this strategy of virus inactivation may prove beneficial for the production of safe and immunogenic inactivated alphavirus vaccines. opinions or assertions contained herein are the scientific views of the authors and should not be construed as official or necessarily reflecting the views or policies of the Uniformed Services University of the Health Sciences or the Department of Defense, USA.
